Trials / Completed
CompletedNCT01940133
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309
Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- PIQUR Therapeutics AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase I, open label study to determine the Maximum Tolerated Dose(MTD) and the Recommended Phase II Dose (RP2D) in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PQR309 | Dosing will be orally, once a day for the duration of the trial. |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2015-03-01
- Completion
- 2015-12-01
- First posted
- 2013-09-12
- Last updated
- 2017-04-12
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT01940133. Inclusion in this directory is not an endorsement.